| |
| |
|
| Insider
Information: |
Aryeh Jason |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
401,047 |
|
|
Indirect Shares
|
890,847 |
|
|
| Direct
Value |
$7,050,652 |
|
|
|
Indirect Value
|
$5,059,198 |
|
|
| Total
Shares |
1,291,894 |
|
|
| Total
Value |
$12,109,850 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2024-04-30 |
76,828 |
2024-04-30 |
56,619 |
Premium* |
|
|
Vaxart Inc |
VXRT |
Director |
2010-12-27 |
0 |
2011-03-15 |
131,783 |
Premium* |
|
|
Myrexis Inc |
MYRX |
Director |
|
0 |
2012-06-15 |
552,145 |
Premium* |
|
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-05-15 |
242,433 |
2017-05-15 |
150,300 |
Premium* |
|
|
Aralez Pharmaceuticals Inc. |
ARLZ |
Director |
2017-05-23 |
15,000 |
2017-05-23 |
0 |
Premium* |
|
|
Merrimack Pharmaceuticals Inc |
MACK |
See Explanation of Res... |
2019-07-16 |
3,802 |
2019-07-11 |
0 |
Premium* |
|
|
Orchestra BioMed Holdings Inc. |
OBIO |
Director |
2023-04-12 |
62,984 |
2023-01-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
175 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2006-09-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
24,700 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2006-09-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,572,668 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2006-09-27 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
34,150 |
|
- |
|
| VXRT |
Vaxart Inc |
officerTitle |
– – – |
2006-10-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,232,650 |
|
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2011-10-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
67,866 |
|
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2012-06-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
151,078 |
|
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Director |
– • – |
2016-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
47,287 |
|
- |
|
| MACK |
Merrimack Pharmaceuticals... |
See Explanation of Responses |
– – • |
2019-07-11 |
4 |
B |
$5.71 |
$571 |
D/D |
100 |
100 |
2.37 |
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2012-05-25 |
4 |
B |
$2.47 |
$378 |
I/I |
153 |
521,951 |
2.02 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-03-15 |
4 |
S |
$5.93 |
$1,186 |
I/I |
(200) |
370,620 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2019-03-13 |
4 |
B |
$112.51 |
$22,727 |
I/I |
202 |
51,594 |
2.1 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-03-24 |
4 |
AS |
$6.24 |
$1,460 |
I/I |
(234) |
251,883 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2019-05-14 |
4 |
AB |
$112.51 |
$28,128 |
D/D |
250 |
59,368 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2019-05-20 |
4 |
AB |
$112.01 |
$28,003 |
D/D |
250 |
59,618 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2019-05-29 |
4 |
AB |
$111.01 |
$27,753 |
D/D |
250 |
59,868 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2019-05-30 |
4 |
AB |
$110.01 |
$27,503 |
D/D |
250 |
60,118 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2019-06-11 |
4 |
AB |
$107.01 |
$26,753 |
D/D |
250 |
61,703 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2019-07-29 |
4 |
AB |
$106.01 |
$26,503 |
D/D |
250 |
61,953 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-06-03 |
4 |
S |
$5.81 |
$1,499 |
I/I |
(258) |
251,625 |
0 |
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2012-05-22 |
4 |
B |
$2.46 |
$645 |
I/I |
262 |
520,798 |
2.02 |
- |
|
| MACK |
Merrimack Pharmaceuticals... |
See Explanation of Responses |
– – • |
2019-07-16 |
4 |
B |
$5.44 |
$1,643 |
D/D |
302 |
3,802 |
2.37 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2017-05-15 |
4 |
B |
$8.95 |
$3,231 |
D/D |
361 |
242,433 |
2.31 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-11-19 |
4 |
S |
$5.25 |
$2,431 |
I/I |
(463) |
196,020 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2018-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
493 |
59,118 |
0 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2012-10-11 |
4 |
OE |
$10.00 |
$5,000 |
I/I |
500 |
155,078 |
0 |
- |
|
175 Records found
|
|
Page 1 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
